Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason T Huse

Showing results (121-130 of 188) with videos related to

Pageof 19
Sort By:
Nature Genetics|November 29, 2017
Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistenceSevin Turcan, Vladimir Makarov, Julian Taranda, et al.
Plos One|June 6, 2017
A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumorsOren J Becher, Nathan E Millard, Shakeel Modak, et al.
Neuro-Oncology|December 18, 2012
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant gliomaAntonio Omuro, Timothy A Chan, Lauren E Abrey, et al.
Non-Coding RNA Research|February 2, 2026
Exploring CSF microRNA signatures as diagnostic biomarkers in adult-type diffuse gliomasMaryam Pirhoushiaran, Kamilah Walker-Charles, Tsung-Hung Yao, et al.
Cancer Cell|September 10, 2024
Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrenceSpencer S Watson, Anoek Zomer, Nadine Fournier, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
Integrated single cell spatial multi-omics landscape of WHO grades 2-4 diffuse gliomas identifies locoregional metabolomic regulators of glioma growthYanxia Ma, Shamini Ayyadhury, Sanjay Singh, et al.
Neuro-Oncology|July 6, 2019
The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patientsCraig Horbinski, Keith L Ligon, Priscilla Brastianos, et al.
Nature|February 21, 2012
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotypeSevin Turcan, Daniel Rohle, Anuj Goenka, et al.
Nature Communications|March 15, 2018
Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodelingCarla Danussi, Promita Bose, Prasanna T Parthasarathy, et al.
Nature Communications|January 6, 2022
Author Correction: Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodelingCarla Danussi, Promita Bose, Prasanna T Parthasarathy, et al.
Pageof 19

Showing results (121-130 of 188) with videos related to

Sort By:
Pageof 19
Nature Genetics|November 29, 2017
Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistenceSevin Turcan, Vladimir Makarov, Julian Taranda, et al.
Plos One|June 6, 2017
A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumorsOren J Becher, Nathan E Millard, Shakeel Modak, et al.
Neuro-Oncology|December 18, 2012
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant gliomaAntonio Omuro, Timothy A Chan, Lauren E Abrey, et al.
Non-Coding RNA Research|February 2, 2026
Exploring CSF microRNA signatures as diagnostic biomarkers in adult-type diffuse gliomasMaryam Pirhoushiaran, Kamilah Walker-Charles, Tsung-Hung Yao, et al.
Cancer Cell|September 10, 2024
Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrenceSpencer S Watson, Anoek Zomer, Nadine Fournier, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
Integrated single cell spatial multi-omics landscape of WHO grades 2-4 diffuse gliomas identifies locoregional metabolomic regulators of glioma growthYanxia Ma, Shamini Ayyadhury, Sanjay Singh, et al.
Neuro-Oncology|July 6, 2019
The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patientsCraig Horbinski, Keith L Ligon, Priscilla Brastianos, et al.
Nature|February 21, 2012
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotypeSevin Turcan, Daniel Rohle, Anuj Goenka, et al.
Nature Communications|March 15, 2018
Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodelingCarla Danussi, Promita Bose, Prasanna T Parthasarathy, et al.
Nature Communications|January 6, 2022
Author Correction: Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodelingCarla Danussi, Promita Bose, Prasanna T Parthasarathy, et al.
Pageof 19